Icon Plc’s (ICLR) Hold Rating Reaffirmed at Jefferies Group LLC
Icon Plc (NASDAQ:ICLR)‘s stock had its “hold” rating reiterated by investment analysts at Jefferies Group LLC in a research note issued on Thursday.
A number of other equities research analysts also recently issued reports on ICLR. Zacks Investment Research downgraded shares of Icon Plc from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. Evercore ISI lifted their price target on shares of Icon Plc from $91.50 to $92.00 and gave the company an “outperform” rating in a research report on Friday, April 28th. Finally, Mizuho began coverage on shares of Icon Plc in a research report on Thursday, March 23rd. They set a “neutral” rating and a $66.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Icon Plc has an average rating of “Hold” and an average target price of $80.80.
Icon Plc (NASDAQ:ICLR) opened at 87.69 on Thursday. The firm’s 50-day moving average price is $81.59 and its 200 day moving average price is $80.31. The stock has a market cap of $4.72 billion, a PE ratio of 18.20 and a beta of 0.63. Icon Plc has a 12-month low of $63.04 and a 12-month high of $89.15.
Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, April 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.02. Icon Plc had a net margin of 15.60% and a return on equity of 29.47%. The company had revenue of $432 million during the quarter, compared to the consensus estimate of $432.21 million. During the same period last year, the firm earned $1.12 EPS. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. Analysts anticipate that Icon Plc will post $5.17 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Icon Plc’s (ICLR) Hold Rating Reaffirmed at Jefferies Group LLC” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/05/11/jefferies-group-llc-reaffirms-hold-rating-for-icon-plc-iclr-2.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Icon Plc by 27.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,460 shares of the medical research company’s stock valued at $111,000 after buying an additional 312 shares during the period. Flinton Capital Management LLC acquired a new position in shares of Icon Plc during the fourth quarter valued at $125,000. US Bancorp DE increased its position in shares of Icon Plc by 4.0% in the third quarter. US Bancorp DE now owns 1,650 shares of the medical research company’s stock valued at $128,000 after buying an additional 64 shares during the period. Quantbot Technologies LP increased its position in shares of Icon Plc by 40.9% in the first quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock valued at $161,000 after buying an additional 587 shares during the period. Finally, IFP Advisors Inc increased its position in shares of Icon Plc by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock valued at $178,000 after buying an additional 59 shares during the period. Institutional investors own 88.14% of the company’s stock.
Icon Plc Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.